NASDAQ:BPTSY Biophytis (BPTSY) Stock Price, News & Analysis → Automatic Income (from home) (From Awesomely, LLC) (Ad) Free BPTSY Stock Alerts $8.26 -0.01 (-0.12%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$8.26▼$8.2650-Day Range N/A52-Week Range$5.44▼$142.00Volume281 shsAverage Volume3,082 shsMarket Capitalization$2.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsSEC FilingsSocial Media Get Biophytis alerts: Email Address Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About BiophytisBiophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Read More BPTSY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPTSY Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive BPTSY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biophytis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BPTSY CUSIPN/A CIK1768946 Webwww.biophytis.com Phone33-1-44-27-23-00FaxN/AEmployees22Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio0.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($16.18) per share Price / Book-0.51Miscellaneous Outstanding Shares350,000Free Float338,000Market Cap$2.89 million OptionableN/A Beta1.14 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Stanislas Veillet Ph.D. (Age 59)Chairman of the Board & CEO Comp: $373.39kMr. Nicolas Fellmann (Age 56)Chief Financial Officer Mr. Waly Dioh Ph.D. (Age 55)Chief Clinical Operating Officer Dr. Pierre J. Dilda Ph.D. (Age 54)Chief Scientific Officer Dr. Rene Lafont (Age 78)Scientific Advisor & Member of Scientific Advisory Board Dr. Rob van Maanen FFPM (Age 53)M.B.A., M.D., Chief Medical Officer Mr. Edouard Bieth (Age 44)Chief Business Officer Ms. Chiara BaccelliChief Pharmaceutical Operations Officer & Quality Assurance DirectorMs. _ TeylanFinancial ControllerMore ExecutivesKey CompetitorsNotable LabsNASDAQ:NTBLAridis PharmaceuticalsNASDAQ:ARDSBiophytisNASDAQ:BPTSNovaBay PharmaceuticalsNYSE:NBYMustang BioNASDAQ:MBIOView All Competitors BPTSY Stock Analysis - Frequently Asked Questions How have BPTSY shares performed in 2024? Biophytis' stock was trading at $8.50 at the start of the year. Since then, BPTSY stock has decreased by 2.8% and is now trading at $8.26. View the best growth stocks for 2024 here. How do I buy shares of Biophytis? Shares of BPTSY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BPTSY) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubThe Presidential candidate you should REALLY be worried aboutStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biophytis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.